Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
Department of Orthopaedics, The Second Hospital, Anhui Medical University, 230601, Hefei, Anhui, People's Republic of China.
Jun
J
Li
Yunfeng
Y
Yao
Juehua
J
Jing
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D018719:Erb-b2 Receptor Tyrosine Kinases